Early Detection Test for Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a new blood test called the GRAIL MCED test, which aims to detect multiple types of cancer early. GRAIL, a company formed by DNA-sequencing giant Illumina, is developing the GRAIL MCED test to detect multiple cancer types early. It targets people who are already recommended for cancer screening. The test works by looking for cancer-related DNA in the blood, and if found, further tests are done to confirm and locate the cancer.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it mentions that adjuvant hormone therapy for cancer is allowed, so you might be able to continue some treatments. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the Multi-Cancer Early Detection Test treatment?
Is the Multi-Cancer Early Detection Test safe for humans?
The Multi-Cancer Early Detection Test is generally considered safe, but there are potential risks such as false positive and negative results, which could lead to unnecessary stress or treatment. Large-scale studies are being conducted to better understand these risks and their impact on health outcomes.14678
How is the Multi-Cancer Early Detection Test different from other cancer detection methods?
The Multi-Cancer Early Detection Test is unique because it uses a blood test to detect signals from multiple types of cancer at once, unlike current screening methods that focus on individual cancers. This test can identify the cancer's origin with high accuracy and has a low rate of false positives, potentially improving early detection and reducing the need for multiple separate screenings.12789
Research Team
Celine Marquez, MD
Principal Investigator
GRAIL, Inc.
Eligibility Criteria
This trial is for individuals at least 50 years old who can consent to participate and are eligible for cancer screening. They shouldn't have had invasive cancer treatment in the last 3 years, except hormone therapy for breast or prostate cancer. Participants must be registered patients at a participating center and not pregnant.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Diagnostic Procedures
Participants with a 'cancer signal detected' test result undergo diagnostic procedures to determine if they have cancer
Follow-up
Participants are monitored for safety and effectiveness after diagnostic procedures
Treatment Details
Interventions
- Multi-Cancer Early Detection Test
Find a Clinic Near You
Who Is Running the Clinical Trial?
GRAIL, Inc.
Lead Sponsor
GRAIL, LLC
Lead Sponsor